Lisata Therapeutics (STU:8NE) Cyclically Adjusted PB Ratio: 0.03 (As of Aug. 17, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8NE Lisata Therapeutics Inc STU:8NE
38 GF Score
Price €0.92
! 3 Warning Signs
View Full Analysis

What is Lisata Therapeutics Cyclically Adjusted PB Ratio?

Lisata Therapeutics STU:8NE -2.13% 38 Cyclically Adjusted PB Ratio is 0.03 as of Aug. 17, 2026, which is 50% below its 10-year median of 0.06. GuruFocus rates STU:8NE with a GF Score™ of 38/100. The stock has 3 warning signs investors should review. Among 692 Biotechnology companies, Lisata Therapeutics ranks better than 96.1% on this metric.

As of today (2026-08-17), Lisata Therapeutics's current share price is €0.92. Lisata Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €28.85. Lisata Therapeutics's Cyclically Adjusted PB Ratio for today is 0.03.

The historical rank and industry rank for Lisata Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:8NE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.06   Max: 0.19
Current: 0.03

During the past years, Lisata Therapeutics's highest Cyclically Adjusted PB Ratio was 0.19. The lowest was 0.01. And the median was 0.06.

STU:8NE's Cyclically Adjusted PB Ratio is ranked better than
96.1% of 692 companies
in the Biotechnology industry
Industry Median: 1.635 vs STU:8NE: 0.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lisata Therapeutics's adjusted book value per share data for the three months ended in Jun. 2026 was €0.785. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €28.85 for the trailing ten years ended in Jun. 2026.

Shiller PE for Stocks: The True Measure of Stock Valuation

Lisata Therapeutics  (STU:8NE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.

Lisata Therapeutics Cyclically Adjusted PB Ratio Related Terms

Lisata Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Lisata Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics Cyclically Adjusted PB Ratio Chart

Lisata Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.02 0.03 0.06 0.05

Lisata Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.07 0.05 0.15 0.10

STU:8NE vs CYCN, OSRH, ICU: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Lisata Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lisata Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:8NE
38GF Score
Lisata Therapeutics Inc STU:8NE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lisata Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lisata Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.92/28.85
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Lisata Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.785/333.9520*333.9520
=0.785

Current CPI (Jun. 2026) = 333.9520.

Lisata Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 17.569 241.428 24.302
201612 8.480 241.432 11.730
201703 -1.240 243.801 -1.699
201706 81.540 244.955 111.165
201709 71.252 246.819 96.406
201712 67.528 246.524 91.476
201803 57.950 249.554 77.548
201806 57.779 251.989 76.572
201809 53.669 252.439 70.999
201812 50.397 251.233 66.990
201903 44.349 254.202 58.262
201906 38.170 256.143 49.765
201909 33.033 256.759 42.964
201912 26.687 256.974 34.681
202003 22.010 258.115 28.477
202006 28.897 257.797 37.433
202009 24.780 260.280 31.794
202012 20.675 260.474 26.507
202103 23.349 264.877 29.438
202106 21.949 271.696 26.978
202109 21.046 274.310 25.622
202112 20.483 278.802 24.535
202203 19.909 287.504 23.125
202206 19.297 296.311 21.748
202209 9.252 296.808 10.410
202212 7.956 296.797 8.952
202303 7.119 301.836 7.876
202306 6.579 305.109 7.201
202309 6.097 307.789 6.615
202312 5.417 306.746 5.897
202403 4.762 312.332 5.092
202406 4.270 314.175 4.539
202409 3.648 315.301 3.864
202412 3.358 315.605 3.553
202503 2.721 319.799 2.841
202506 2.114 322.561 2.189
202509 1.690 324.800 1.738
202512 1.436 324.054 1.480
202603 1.038 330.213 1.050
202606 0.785 333.952 0.785

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

What does a Cyclically Adjusted PB Ratio of 0.03 mean?
Lisata Therapeutics (STU:8NE) has a Cyclically Adjusted PB Ratio of 0.03 as of Aug. 17, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Lisata Therapeutics and its competitors. This is 50% below median its historical median of 0.06. Over the past decade, Lisata Therapeutics' Cyclically Adjusted PB Ratio has ranged from 0.01 to 0.19. According to the industry distribution chart, Lisata Therapeutics ranks #27 out of 692 companies in the Biotechnology industry, placing it in the top 3.9%.
Is Lisata Therapeutics' Cyclically Adjusted PB Ratio too high?
Lisata Therapeutics' current Cyclically Adjusted PB Ratio of 0.03 is 50% below median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.19. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.64. Lisata Therapeutics' value of 0.03 is 98.2% below this industry median. Based on the distribution chart, Lisata Therapeutics ranks #27 out of 692 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lisata Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Lisata Therapeutics' Cyclically Adjusted PB Ratio compare to CYCN and OSRH?
According to the Biotechnology industry distribution chart, Lisata Therapeutics ranks #27 out of 692 companies for Cyclically Adjusted PB Ratio. This places Lisata Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PB Ratio is 1.64. Lisata Therapeutics' value of 0.03 is 98.2% below this benchmark. Historically, Lisata Therapeutics' own Cyclically Adjusted PB Ratio has ranged from 0.01 to 0.19 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 1.64, Lisata Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.64, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lisata Therapeutics's current Cyclically Adjusted PB Ratio of 0.03 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Lisata Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lisata Therapeutics's current Cyclically Adjusted PB Ratio is 0.03, which is 50% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lisata Therapeutics stock overvalued right now?
Lisata Therapeutics (STU:8NE) has a current Cyclically Adjusted PB Ratio of 0.03. The current Cyclically Adjusted PB Ratio is 0.03, which is 50% below median its 10-year median of 0.06 and 98.2% below the Biotechnology industry median of 1.64. Lisata Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Lisata Therapeutics (STU:8NE), the current Cyclically Adjusted PB Ratio is 0.03 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lisata Therapeutics Business Description

Other Exchanges LSTA:USA0HS8:UK8NE:Germany
Address 110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
38GF Score

Get the complete analysis for STU:8NE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.92
Price